HIGH-VOLUME · HOSP-HEAVY
empagliflozin Side Effects
empagliflozin (also sold as Jardiance) is HIGH-VOLUME in this FAERS book #119 of 524 by FAERS report count. Signature opener: HOSP-HEAVY - 32.9% mention hospitalization (20,281 reports).
Data updated 2026-05-15
- 61,560
- FAERS reports
FAERS voluntary reports, 2013 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.
empagliflozin: 32.9% mention hospitalization (20,281 reports). Death stamp DEATH-MARKED; volume band HIGH-VOLUME #119 of 524 by FAERS report count.
High-report extract for empagliflozin (Jardiance): 61,560 FAERS rows (2013-2025). Top named reactions: DIABETIC KETOACIDOSIS, NAUSEA, BLOOD GLUCOSE INCREASED. Outcome stamps DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED. FAERS is voluntary signal detection, not incidence.
Counts from the openFDA FAERS extract (2013–2025). Stamps CASELOAD · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.
DIABETIC KETOACIDOSIS leads 3,773 of 61,560 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (14,375 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 3,028 reports (4.9% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 1,403 |
| ACUTE KIDNEY INJURY | 140 |
| CARDIAC ARREST | 133 |
| CARDIAC FAILURE | 110 |
| PNEUMONIA | 103 |
| SEPSIS | 101 |
| DYSPNOEA | 99 |
| DIABETIC KETOACIDOSIS | 90 |
| METABOLIC ACIDOSIS | 86 |
| HYPOTENSION | 80 |
| VOMITING | 79 |
| LACTIC ACIDOSIS | 73 |
| MYOCARDIAL INFARCTION | 71 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 69 |
| ASTHENIA | 67 |
| DIARRHOEA | 67 |
| FALL | 65 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 65 |
| EUGLYCAEMIC DIABETIC KETOACIDOSIS | 64 |
Reactions in Hospitalization Reports
Hospitalization is HEAVY (20,281, 32.9% of the book). Top reactions in those rows:
| Reaction | Reports |
|---|---|
| DIABETIC KETOACIDOSIS | 2,725 |
| EUGLYCAEMIC DIABETIC KETOACIDOSIS | 1,478 |
| VOMITING | 1,376 |
| NAUSEA | 1,270 |
| ACUTE KIDNEY INJURY | 1,209 |
| DYSPNOEA | 1,017 |
| KETOACIDOSIS | 1,012 |
| DIARRHOEA | 1,001 |
| DEHYDRATION | 929 |
| URINARY TRACT INFECTION | 924 |
| PNEUMONIA | 773 |
| FALL | 740 |
| HYPOTENSION | 738 |
| FOURNIER^S GANGRENE | 706 |
| ASTHENIA | 682 |
| WEIGHT DECREASED | 659 |
| FATIGUE | 640 |
| SEPSIS | 605 |
| CARDIAC FAILURE | 600 |
How to read empagliflozin FAERS figures (CASELOAD · DEATH-MARKED · HOSP-HEAVY)
FAERS holds 61,560 voluntary reports linked to empagliflozin (Jardiance), 2013-2025. Death is listed on 3,028 (4.9%). Hospitalization appears on 20,281 (32.9%). Top co-reported indication: Product Used For Unknown Indication.
CASELOAD books overweight common drugs and loud reporting cultures; HOSP-HEAVY is the page opener, not a per-patient risk.
Read with empagliflozin
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-HEAVY stamps.
ABS(total_reports) peer at 61,536 FAERS cases (Δ 24 lighter vs empagliflozin); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 60,533 FAERS cases (Δ 1,027 lighter vs empagliflozin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 62,650 FAERS cases (Δ 1,090 heavier vs empagliflozin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.
ABS(total_reports) peer at 63,536 FAERS cases (Δ 1,976 heavier vs empagliflozin); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-HEAVY · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 57.2 pp vs empagliflozin's DEATH-MARKED): CASELOAD · HOSP-MID.
empagliflozin stamps DEATH-MARKED · HOSP-HEAVY; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload CASELOAD and the label guide.